[1] Zhang Z, Lai E C H, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Int J Surg,2015,20:8-16. [2] Sun J, Guo R, Bi X, et al. Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 Edition)[J]. Liver Cancer,2022,11(4):315-328. [3] Younossi Z M, Wong G, Anstee Q M, et al. The global burden of liver disease[J]. Clin Gastroenterol Hepatol,2023,21(8):1978-1991. [4] Pengfei L, Xing L, Yanming X, et al. The importance and necessity of establishing technical specifications for the registration of traditional Chinese medicine clinical studies[J]. J Altern Complement Med,2014,20(1):65-66. [5] The L O. Clinical trial registry reporting: a transparent solution needed[J]. Lancet Oncol,2019,20(6):741. [6] Kokabi N, Arndt-Webster L, Chen B, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study[J]. Eur J Nucl Med Mol Imaging,2023,50(6):1743-1752. [7] 肖婷婷,邓坦. 原发性肝癌合并门静脉癌栓治疗进展[J]. 安徽医药,2025,29(3):460-466. [8] Kudo M, Matsui O, Izumi N, et al. JSH Consensus-Based Clinical Practice Guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan[J]. Liver Cancer,2014,3(3-4):458-468. [9] Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update[J]. Liver Cancer,2021,10(3):181-223. [10] 秦晓宽,孙凯,孙传睿,等. 中医药治疗腰椎间盘突出症的临床试验注册现状分析[J]. 世界中医药,2023,18(21):3013-3017. [11] Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase Ⅲ, randomized clinical trial (LAUNCH)[J]. J Clin Oncol,2023,41(1):117-127. [12] 王欢,程树群. 肝癌合并门静脉癌栓的早期诊断[J]. 现代肿瘤医学,2025,33(01):142-148. [13] 吴伟珍,戚茂建,唐海军,等. 肝细胞癌合并门静脉癌栓危险因素分析及诊断模型构建[J]. 肿瘤学杂志,2025,31(6):481-487. [14] Russo F P, Imondi A, Lynch E N, et al. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review[J]. Dig Liver Dis,2018,50(7):640-646. [15] 杨恒,朱丽虹,荆涛,等. 国内肠易激综合征中医临床试验注册现状分析[J]. 环球中医药,2024,17(12):2522-2525. [16] Zhang X, Liang F, Lau C T, et al. Standards for reporting interventions in clinical trials of tuina/massage (STRICTOTM): extending the CONSORT statement[J]. J Evid Based Med,2023,16(1):68-81. [17] Schulz K F, Altman D G, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials[J]. J Clin Epidemiol,2010,63(8):834-840. [18] 施泽阳,孙源,马文欣,等. 盲法质量评价方法在中医临床试验中的应用[J]. 中国实验方剂学杂志,2024,30(3):75-80. |